algorithms immunospot cellular technology limited 7 0 18 1 prism graphpad software (Cellular Technology Ltd)
Cellular Technology Ltd is a verified supplier 
Cellular Technology Ltd manufactures this product 
99
Structured Review
Cellular Technology Ltd
algorithms immunospot cellular technology limited 7 0 18 1 prism graphpad software
Algorithms Immunospot Cellular Technology Limited 7 0 18 1 Prism Graphpad Software, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 2207 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software%2C+algorithm+prism+7/ImmunoSpot+Software/pm42805178-261-237-238
Average 99 stars, based on 2207 article reviews
Algorithms Immunospot Cellular Technology Limited 7 0 18 1 Prism Graphpad Software, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 2207 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software%2C+algorithm+prism+7/ImmunoSpot+Software/pm42805178-261-237-238
Average 99 stars, based on 2207 article reviews
algorithms immunospot cellular technology limited 7 0 18 1 prism graphpad software - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
Software:Article Title: Fast and Ultra-Fast mRNA-Engineered Anti-CA125/MUC16 CAR-T-Cells: An In Vitro Study Article Snippet: After completion of the detection procedure, the plates were scanned using an ImmunoSpot S6 Ultra Analyzer (Cellular Technology Limited). .. Fluorescent spots corresponding to each analyte were enumerated using Article Title: Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01 Article Snippet: Interferon (IFN)-γ secretion from T cells was detected by enzyme-linked immunosorbent spot (ELISpot) assay using the Human IFN-γ ELISpot PRO kit (MABTECH, Stockholm, Sweden) according to the manufacturer’s instruction. .. Spots were captured and analyzed by an automated ELISpot reader, ImmunoSPOT S4 (Cellular Technology, Shaker Heights, Ohio, USA) and the Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Automated:Article Title: Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01 Article Snippet: Interferon (IFN)-γ secretion from T cells was detected by enzyme-linked immunosorbent spot (ELISpot) assay using the Human IFN-γ ELISpot PRO kit (MABTECH, Stockholm, Sweden) according to the manufacturer’s instruction. .. Spots were captured and analyzed by an automated ELISpot reader, ImmunoSPOT S4 (Cellular Technology, Shaker Heights, Ohio, USA) and the Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Article Title: A Nitric Oxide–Based STING Agonist Nanoadjuvant With ICD‐Derived Membrane Antigens Unleashes Robust Antitumor Immunity Article Snippet: .. Air‐dried plates were analyzed using an automated Enzyme-linked Immunospot:Article Title: Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01 Article Snippet: Interferon (IFN)-γ secretion from T cells was detected by enzyme-linked immunosorbent spot (ELISpot) assay using the Human IFN-γ ELISpot PRO kit (MABTECH, Stockholm, Sweden) according to the manufacturer’s instruction. .. Spots were captured and analyzed by an automated ELISpot reader, ImmunoSPOT S4 (Cellular Technology, Shaker Heights, Ohio, USA) and the Article Title: A Nitric Oxide–Based STING Agonist Nanoadjuvant With ICD‐Derived Membrane Antigens Unleashes Robust Antitumor Immunity Article Snippet: .. Air‐dried plates were analyzed using an automated Flow Cytometry:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Cytometry:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Coagulation:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. Reversed-phase High-Performance Liquid Chromatography:Article Title: Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Article Snippet: Despite the clinical success of immune checkpoint blockade therapy, most persons do not benefit because of inadequate efficacy, primary or acquired resistance and/or immune-related toxicities.. Here we developed an erythrocyte–antibody conjugate in which anti-PD1 antibodies are covalently linked to erythrocyte membranes (αPD1-Ery).. Unlike conventional antibodies, αPD1-Ery accumulates in the spleen, where it remodels the immune landscape by expanding effector T cells and r ed uc ing i mm un os up pr essive myeloid cells. other:Article Title: Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Methylcellulose Sigma-Aldrich Cat# M7027 Saponin Sigma-Aldrich Cat# 47036 4% paraformaldehyde in PBS Alfa Aesar Cat# J61899.AP SMARTscribe Reverse Transcriptase Takara Cat# 639538 1-Step Ultra TMB-ELISA Thermo Fisher Scientific Cat# 34028 Kinetics buffer FortéBio 18-1105 Critical commercial assays Universal Mycoplasma Detection Kit ATCC Cat# 30-1012K QIAGEN Multiplex PCR Kit Qiagen Cat# 206143 Plasmid Maxi Kit Qiagen Cat #12162 RNeasy Plus Mini kit Qiagen Cat# 74134 QIAamp Viral RNA extraction kit Qiagen Cat# 52904 SuperScript IV One-Step RT-PCR kit Thermo Fisher Scientific Cat# 12594025 QIAquick PCR Purification Kit Qiagen Cat# 28104 FabALACTICA Fab kit Midispin Genovis A2-AFK-100 Deposited data MeV-15 + MeV-104/MeV-F Protein DataBank PDB: 9YBY MeV-15 + MeV-104/MeV-F Electron Microscopy DataBank EMD-72759 MeV F (prefusion stabilized) Protein DataBank PDB: 8UUP Fab fragment Protein DataBank PDB: 12E8 MeV F + Fab77 Protein DataBank PDB: 8UT2 Experimental models: Cell lines Mouse-human HMMA 2.5 myeloma cell line Dr. L. Cavacini N/A VeroSLAM BEI Resources NR-55500 Vero ATCC CCL81 Human: Expi293F Thermo Fisher Scientific Cat# A14527; RRID:CVCL_D615 Hamster: ExpiCHO Thermo Fisher Scientific Cat# A29127; RRID:CVCL_5J31 Experimental models: Organisms/strains SLAMF1 IFNAR knockout mice Branka Horvat Sellin et al.27 Oligonucleotides CpG (ZOEZOEZZZZZOEEZOEZZZT oligonucleotide) Invitrogen N/A Recombinant DNA pANTS_MeV-15_mCisK_hG1 This paper N/A pANTS_MeV-16_mCisL_hG1 This paper N/A pANTS_MeV-17_mCisK_hG1 This paper N/A pANTS_MeV-22_mCisK_hG1 This paper N/A pANTS_MeV-104_mCisK_hG1 This paper N/A pANTS_MeV-15_mCisK_FAB This paper N/A pANTS_MeV-104_mCisK_FAB This paper N/A pVVC_77.4_mCisK_hG1 Zyla et al.18 N/A MeV_PreF_V3 This paper, Hashiguchi et al.12 N/A Software and algorithms |